Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHABELINA FE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CHABELINA FE is a combination of conjugated estrogens (CE) and bazedoxifene, a selective estrogen receptor modulator (SERM). CE binds to estrogen receptors (ERα and ERβ) to activate estrogenic pathways in tissues such as bone, while bazedoxifene acts as an antagonist at ERs in the breast and uterus, reducing the risk of endometrial hyperplasia. The net effect is estrogen receptor agonism in bone and antagonism in breast and endometrium.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Moderate to severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis
Prevention of pregnancy (FDA-approved)
Orally, 1 tablet once daily for 21 days, then 7 days of placebo; each active tablet contains 30 mcg ethinyl estradiol and 3 mg drospirenone.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life: 8-12 hours; clinically relevant for dosing interval in moderate renal impairment
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Conjugated estrogens are metabolized primarily in the liver via hydroxylation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9, CYP2C19) and conjugation (glucuronidation and sulfation). Bazedoxifene is metabolized mainly by UGT1A1 and UGT1A3 glucuronidation, with minor involvement of CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily renal; 40-60% excreted unchanged in urine; biliary/fecal elimination accounts for <5%
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
~70-80% bound to serum albumin and alpha-1 acid glycoprotein
~99% bound to serum albumin and sex hormone-binding globulin.
2-3 L/kg; indicates extensive tissue distribution, including passage into CSF
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 95-100%
Oral: ~70% due to first-pass metabolism.
Contraindicated in GFR < 30 m L/min/1.73 m²; no adjustment needed for GFR ≥ 30 m L/min/1.73 m².
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh Class C; use not recommended in Child-Pugh Class A or B due to potential steroid hormone clearance issues.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Post-menarchal adolescents: same as adult dosing; safety and efficacy in pre-menarchal patients not established.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women; no specific dose adjustment recommended for elderly patients with normal hepatic and renal function.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Estrogen Plus Progestin Therapy: Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis were reported in postmenopausal women (50-79 years of age) during 5.6 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of invasive breast cancer and coronary heart disease. Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations of estrogens and progestins were not studied in the WHI and, in the absence of comparable data, these risks should be assumed to be similar.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction. Discontinue if thrombotic events occur or are suspected.,Malignant neoplasms: Increased risk of endometrial cancer with unopposed estrogen; bazedoxifene reduces but does not eliminate this risk. Increased risk of ovarian cancer. May increase risk of breast cancer; discontinue if breast cancer is detected.,Gallbladder disease: Increased risk requiring cholecystectomy.,Hypertriglyceridemia: May cause pancreatitis in patients with elevated triglycerides.,Hepatic impairment: Use caution; may be contraindicated in severe hepatic disease.,Hypothyroidism: May increase thyroid-binding globulin, requiring increased thyroid hormone dose.,Fluid retention: Caution in patients with cardiac or renal impairment.,Hypocalcemia: May occur in patients with hypoparathyroidism.,Hereditary angioedema: Estrogens may exacerbate symptoms.,Porphyria: May exacerbate.,Osteoporosis: Use only for prevention, not treatment.,Dementia: Increased risk of probable dementia in women ≥65 years.,Laboratory tests: Monitor thyroid function, triglycerides, and endometrial status as indicated.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer),Active or history of venous thromboembolism (DVT, PE),Active or history of arterial thromboembolism (stroke, MI),Known anaphylactic reaction or angioedema to any component,Hepatic impairment or disease,Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders,Known or suspected pregnancy
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions with hormonal components. Grapefruit juice may increase estrogen exposure; limit consumption. Iron in placebo pills may be less absorbed with coffee, tea, or dairy; take with vitamin C source enhances absorption. No other dietary restrictions.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
CHABELINA FE contains carbonyl iron, folic acid, and other vitamins/minerals. Carbonyl iron is not associated with increased risk of major malformations. Folic acid is recommended to prevent neural tube defects. No known teratogenic risk in any trimester.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Iron and folic acid are excreted into breast milk in small amounts. Iron supplementation may increase milk iron concentration. No adverse effects reported. M/P ratio not established.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Dose adjustments not typically required. Pregnancy may increase iron requirements; ensure adequate intake. Pharmacokinetic changes (e.g., increased plasma volume) may necessitate higher doses in iron deficiency.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
CHABELINA FE is a combination oral contraceptive containing ethinyl estradiol and drospirenone. It also includes ferrous fumarate (iron supplement) in the placebo pills to reduce iron deficiency anemia risk. Drospirenone has anti-mineralocorticoid activity, which may cause hyperkalemia; caution with medications that increase potassium (e.g., ACE inhibitors, NSAIDs). Monitor for thrombotic events; contracepted in women with hypertension >160/100 mm Hg or migraine with aura. Absorption of drospirenone may be reduced with hepatic impairment.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time; missing pills increases pregnancy risk.,Use backup contraception if starting late or missing pills per package instructions.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden headache, vision changes.,Avoid smoking; smoking increases risk of serious cardiovascular side effects.,Iron in placebo pills may cause dark stools; this is harmless.,Inform your doctor about all medications, especially those affecting potassium levels.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHABELINA FE vs AFIRMELLE, answered by our medical review team.
CHABELINA FE is a Oral contraceptive that works by CHABELINA FE is a combination of conjugated estrogens (CE) and bazedoxifene, a selective estrogen receptor modulator (SERM). CE binds to estrogen receptors (ERα and ERβ) to activate estrogenic pathways in tissues such as bone, while bazedoxifene acts as an antagonist at ERs in the breast and uterus, reducing the risk of endometrial hyperplasia. The net effect is estrogen receptor agonism in bone and antagonism in breast and endometrium.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHABELINA FE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHABELINA FE is: Orally, 1 tablet once daily for 21 days, then 7 days of placebo; each active tablet contains 30 mcg ethinyl estradiol and 3 mg drospirenone.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHABELINA FE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHABELINA FE is classified as Category C. CHABELINA FE contains carbonyl iron, folic acid, and other vitamins/minerals. Carbonyl iron is not associated with increased risk of major malformations. Folic acid is recommended . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.